Ce
I appreciate your attention to my analysis.
I find the charts intriguing, particularly the concepts of "total destruction" and "buying in blood." Despite the short-term risks, the potential for significant gains, such as 10x, 50x, or even 100x returns in the long term, is undeniable.
Upon closer examination of the chart, it appears that shorting activities have lost momentum recently, while earnings have shown consistent growth, with approximately 92% in the green. Although attempts to initiate a short squeeze in recent months resulted in a bull trap, the current situation presents a crucial juncture that appears heavily bearish, yet potentially ripe for the taking.
Regarding the skepticism surrounding the possibility of the stock reaching $1, the remarkably low market cap suggests an underestimation of its potential. I firmly believe that this stock's trajectory is far from its conclusion; rather, it signals the dawn of a promising future.
(Exagen Inc. is a diagnostic company specializing in autoimmune diseases, notably lupus and rheumatoid arthritis.)
I appreciate your attention to my analysis.
I find the charts intriguing, particularly the concepts of "total destruction" and "buying in blood." Despite the short-term risks, the potential for significant gains, such as 10x, 50x, or even 100x returns in the long term, is undeniable.
Upon closer examination of the chart, it appears that shorting activities have lost momentum recently, while earnings have shown consistent growth, with approximately 92% in the green. Although attempts to initiate a short squeeze in recent months resulted in a bull trap, the current situation presents a crucial juncture that appears heavily bearish, yet potentially ripe for the taking.
Regarding the skepticism surrounding the possibility of the stock reaching $1, the remarkably low market cap suggests an underestimation of its potential. I firmly believe that this stock's trajectory is far from its conclusion; rather, it signals the dawn of a promising future.
(Exagen Inc. is a diagnostic company specializing in autoimmune diseases, notably lupus and rheumatoid arthritis.)